Signet Therapeutics Lands on BEYOND Awards Healthcare Tech Excellence List with First-in-Class Diffuse Gastric Cancer Drug SIGX1094

Recently, at the BEYOND Awards 2025 ceremony held at the Venetian Macao's Cotai Expo, SIGNET was honored on the "BEYOND Awards Healthcare Technology Breakthrough List" for its world-first targeted drug for diffuse gastric cancer, SIGX1094, developed using an "organoid + AI" platform. This marks another significant milestone for SIGNET on the international authoritative stage, following its recognition as one of Forbes Asia's 100 to Watch in 2023 and winning the Global Innovation Award 2025.

SIGX1094 is the world’s first targeted drug independently developed by Signet Therapeutics for diffuse gastric cancer. It is the first drug developed based on an organoid and AI technology platform, and also the world’s first dual-target inhibitor of FAK/SRC to enter clinical trials. FAK and its key binding partner SRC form a complex that activates downstream pathways. During drug development, single inhibition of either FAK or SRC was found to be compensated by the other, significantly reducing the drug's anti-tumor efficacy. Therefore, by simultaneously blocking the critical signaling pathways of both FAK and SRC, the limitations of single-target inhibitors were overcome. Relying on its self-developed organoid disease model platform for target validation and efficacy evaluation, and integrating AI-driven drug design from XtalPi (2228.HK), Signet Therapeutics successfully developed SIGX1094, the world’s first targeted drug for diffuse gastric cancer, in just four years. The drug has received Orphan Drug Designation and Fast Track Designation from the U.S. FDA.

BEYOND International Science and Technology Innovation Expo (BEYOND Expo), as one of the most influential technology events in Asia, has attracted more than 800 top global technology companies to participate in this year's expo, jointly exploring the future landscape of technological innovation. The selection for this ranking evaluates local innovation from a global perspective, constructing a leading index through a multi-dimensional and multi-level assessment model that includes R&D strength and innovation ecosystem, market leadership and growth, social responsibility and sustainable development, international strategy and achievements, and future vision and strategic planning. The aim is to identify and honor those forces in the medical technology field that demonstrate exceptional innovation capabilities and achieve "defining industry-leading standards."

SIGNET is a global pioneer in the "organoid + AI" drug development model, recognized as a specialized and innovative enterprise in Shenzhen and certified as a National High-tech Enterprise. The company originated on the campus of Harvard University and officially established its presence in Shenzhen by the end of 2020, having since secured nearly 220 million yuan in financing and project funding. Currently, the company has four drug pipelines, with the lead pipeline developing SIGX1094, the world’s first targeted drug for diffuse gastric cancer. It has obtained IND approval from both the U.S. FDA and China's NMPA, and received Orphan Drug Designation and Fast Track Designation from the U.S. FDA. Phase I clinical trials are currently underway at the Peking University Cancer Hospital.

Signet is not only the phonetic translation of "Signet" but also adheres to the vision of "Hopeful Aspirations, Investigating Things to Attain Knowledge." The company leverages organoid disease models that closely resemble patients' genomic characteristics for critical roles in drug efficacy evaluation and new target discovery. Combined with AI-powered screening, synthesis, and optimization of small-molecule compounds, Signet develops first-in-class innovative targeted drugs. The company has approximately 1500㎡ of R&D space and 500㎡ of animal laboratory space. Signet Therapeutics' organoid platform not only serves its own drug pipeline but also actively empowers large pharmaceutical companies in new drug development. Collaborative partners include Shenzhen Second People's Hospital, the University of Hong Kong, the Hong Kong University of Science and Technology, Shenzhen BioRay Pharma, and Genuine Biotech, contributing to the birth of more innovative drugs.